Month: September 2026

Tripled ridership, more than 50% lower cost per ride, and rapid transit infrastructure deployment

TORONTO, Sept. 24, 2026 (GLOBE NEWSWIRE) — Argo Corporation (TSXV: ARGH) (OTCQX: ARGHF) (“Argo” or the “Company”) today announced that average daily transit ridership in the Town of Bradford West Gwillimbury (“BWG” or the “Town”) has grown to more than 3x the daily ridership of the Town’s previous fixed-route transit system.

Argo launched its proprietary Smart Routing™ transit infrastructure and service in BWG in April 2025. The Town subsequently replaced its previous privately operated fixed-route service with Argo’s on-demand public transit and renewed and expanded its agreement with Argo.

Argo Smart Routing™ Transit in Bradford West Gwillimbury, Canada

• Tripled Ridership: Average daily ridership has grown to more than 3x pre-Argo levels.
• Increased Transit Connections: As previously reported, Argo drove a more than 5x increase in transit connections to Bradford GO.
• Point-to-Point Access: Residents are now picked up where they are and dropped off where they are going, with over 90% of Argo trips including a pickup or drop-off more than 100 metres from the previous fixed-route bus stops.
• Lower Cost per Ride: As previously reported, the Town’s cost per ride declined by more than 50% compared with its previous fixed-route service.
• Rapid Deployment: Argo launched the infrastructure, technology and operations required for Smart Routing™ approximately three months from contract signing.
• Provincial Funding: Ontario has awarded BWG $4,093,337 through the Ontario Transit Investment Fund to support further expansion of on-demand transit.

“Bradford shows how modern transit technology can expand access to opportunity and independence, and give people the freedom to participate fully in their communities,” said Praveen Arichandran, Co-founder and CEO of Argo. “We’re bringing integrated transit infrastructure and operations online in weeks, not years, so more people can realize those benefits sooner.”

Since the BWG launch, Argo has continued the expansion of its Smart Routing™ network in Brampton and Caledon. The Company’s focus remains on expanding the network across Canada, the United States, and internationally.

About Argo

Argo delivers the first-ever vertically and publicly integrated city transit system, designed to augment public transportation and create a network of intelligently routed vehicles that work together to serve and scale to the needs of entire cities, putting people in control of their mobility. Learn more at www.rideargo.com.

Investor Contact Praveen Arichandran Co-founder & CEO Argo Corporation (800) 575-7051	Media Contact Christina Ra Argo Corporation christina@rideargo.com (800) 575-7051

Forward-Looking Information

This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward-looking statements are frequently identified by such words as “may”, “will”, “plan”, “expect”, “anticipate”, “estimate”, “intend” and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. The forward-looking information set out in this news release relates to future events or future performance and includes, without limitation, statements concerning the continued operation and expansion of Smart Routing™ in Bradford West Gwillimbury, the use of provincial funding to support further expansion of on-demand transit, the anticipated benefits of Argo’s Smart Routing™ transit system, potential future expansion to other municipalities, and the Company’s plans to expand its network in Canada, the United States and internationally, the Company’s deployment timelines.

Such forward-looking statements are based on a number of assumptions, including: the continued successful operation of the Bradford West Gwillimbury service; maintaining municipal agreements in good standing; receiving required third-party approvals, consents and integrations; operational readiness; ridership adoption levels; technology performance and reliability; the availability and use of government funding; the availability of municipal procurement opportunities and execution of definitive agreements with new municipalities; and general economic conditions. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including but not limited to: operational challenges; failure to meet contractual requirements; loss of required operating authority, insurance or approvals; third-party integration delays or failures; technology failures or cybersecurity incidents; termination or non-renewal of municipal agreements; failure to secure new municipal contracts; regulatory changes; availability of financing; and general economic conditions. Additional risks and uncertainties are described in more detail in the Company’s securities filings available at www.sedarplus.ca. Actual events or results may differ materially from those projected in the forward-looking statements and readers are cautioned against placing undue reliance thereon. The Company assumes no obligation to revise or update these forward-looking statements except as required by applicable law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6a8d2001-14f6-42a3-b0f6-87401547a9eb

Integrated exploration model identifies multiple priority epithermal and porphyry targets across Fishpot; ~2,000-metre maiden drill program prepares for launch; Company commences trading on OTCQB under INXGF

VANCOUVER, British Columbia, Sept. 24, 2026 (GLOBE NEWSWIRE) — GoldInxs Mining Corp. (“GoldInxs,” or the “Company”) (TSXV: INXS, OTCQB: INXGF) is pleased to announce it has received results from a 53.4-line-kilometre 3D Induced Polarization (“IP”) survey, reprocessed Airborne Magnetic Survey data and a Virtual DRILL™ Elemental Harmonic Resonance (“EHR”) survey on its flagship Fishpot property in Central British Columbia. The combined results have refined multiple priority exploration targets where geophysical responses coincide with surface geology, alteration and geochemical anomalies ahead of the Company’s planned ~2,000-metre maiden drill program.

The Company is also pleased to report that its common shares have commenced trading on the OTCQB Venture Market under the symbol “INXGF“, an important step in broadening GoldInxs’ shareholder base, enhancing accessibility for U.S. investors and providing an additional platform for market visibility as the Company advances its exploration programs in British Columbia.

The integrated geophysical results identified and refined multiple chargeability, resistivity and magnetic features that correlate with existing geological, alteration and surface geochemical information, providing the Company with a more robust framework for prioritizing drill targets ahead of its planned ~2,000-metre maiden drill program. The Virtual DRILL™ Elemental Harmonic Resonance (“EHR”) survey also correlates with the updated geophysical results, resulting in robust multi-discipline exploration targets (refer to the Company’s press release dated August 17, 2026). The Company continues to plan and prepare for its inaugural drill program at Fishpot, located in the broader regional setting of Artemis Gold’s Blackwater Mine and Evolution Mining’s optioned Clisbako property, providing exposure to an active and increasingly established gold exploration region.

Key Highlights

• 53.4 line-kilometer 3D IP survey identified multiple chargeability and resistivity anomalies across the Fishpot property, including responses that correlate with existing surface geology, alteration and geochemical anomalies;
• Airborne magnetic data successfully reprocessed using Magnetization Vector Intensity (“MVI”), improving interpretation of magnetic responses in areas affected by magnetic remanence;
• Virtual DRILL™ Elemental Harmonic Resonance results correlate strongly with the existing and new data, showing its potential for use on other parts of the property;
• New geophysical information evaluated as part of an integrated exploration model combining 3D IP chargeability and resistivity responses with magnetic data, Virtual DRILL™ data, geological mapping, alteration and surface geochemistry, refining priority target zones based on areas where multiple exploration datasets converge;
• Planning and targeting continues for a ~2,000-metre maiden drill program, with drill pad locations and hole orientations being finalized based on the integrated geological and geophysical model.

3D Induced Polarization Results

In late July 2026, the Company engaged SJ Geophysics to complete a 3D IP survey on the Fishpot property. Data was acquired from July 28^th to August 19^th over 53.4 line kilometers in 8 lines overlapping with the main mineralized zones on the property. Results show large zones of subsurface resistivity and chargeability anomalies, many of which correlate with the surface geochemical anomalies and geology. Of particular note is the overlapping resistivity and chargeability anomalies that underlie the Lightening Zone, as well as the chargeability high, magnetic low zone that surrounds the previously identified magnetic high “lobe”, now known as the BullsEye target. The circular magnetic and chargeability response at BullsEye is considered a priority feature for follow-up exploration and may be consistent with geological characteristics observed in copper porphyry systems; drilling will be required to test this interpretation.

The 3D IP survey provides an important additional layer of subsurface information to complement the Company’s existing surface exploration dataset. Of particular interest are areas where IP responses coincide spatially with mapped geological contacts, alteration zones and anomalous surface geochemistry. The Company believes these areas warrant additional investigation and have contributed significantly to the prioritization of drill targets for the upcoming maiden drill program.

Magnetic Survey Reprocessing Results

The previously collected airborne magnetic, radiometric, and VLF-EM survey data obtained in 2025 was provided to in3D Geoscience Inc. who reprocessed the data using Magnetization Vector Intensity (“MVI”). MVI re-models the data to reduce the impacts of magnetic remanence, which can cause certain anomalies to be offset from their true locations. Several zones of magnetic remanence were identified in the original data and the resultant MVI model improved accuracy of the data in those areas.

Virtual DRILL™

The Company has received the results from the Virtual DRILL™ EHR survey. Several target areas have been identified which correlate to the existing and newly acquired exploration data. The Virtual DRILL™ EHR survey was completed independently of the newly acquired 3D IP and reprocessed magnetic data. Several EHR target areas subsequently demonstrated spatial correlation with the updated geophysical and existing geological datasets, providing an additional layer of target validation. The maiden drill program will provide an opportunity to test selected EHR targets against conventional geological and geophysical interpretations.

The Company has now integrated six exploration datasets at Fishpot; IP chargeability, IP resistivity, magnetic data, Virtual DRILL™ EHR results, geological mapping, alteration and surface geochemistry, to prioritize areas where multiple indicators overlap.

Figure 1: Induced Polarization Survey results showing Resistivity and Chargeability.

Figure 2: Magnetics MVI reprocessing results and Virtual Drill EHR results

Drill Planning Update

Integrating the new and reprocessed geophysical data with the existing property data has allowed the Company to refine their drill targets ahead of the maiden drill program planned for the Fishpot property. Overlapping geological surface information, including geochemistry, alteration, and geological mapping data with new and updated geophysical data has highlighted several promising surface and subsurface anomalies on the property. In light of the new anomalies, the Company has created several identified priority gold-silver epithermal target zones including the ‘Lightening’ zone, the ‘Luftballon’ zone’, the ‘Thriller’ zone, the ‘Believin’ zone, the “Southside’ zone, and a copper porphyry target called the ‘BullsEye’. Further refinement will be ongoing as it relates to specific drill pad locations until drilling commences, and modifications may be made as the drill program progresses.

• Lightening Zone: Resistivity and chargeability IP anomaly overlain by intense silica alteration and overlapping geochemical anomalies.
• Luftballon Zone: Magnetic low with a moderate chargeability anomaly located north of the magnetic high lobe. Intense silica alteration with overlapping geochemical anomalies.
• Thriller Zone: Magnetic low zone with resistivity anomaly, silica “ribs” present on surface.
• Believin’ Zone: Resistivity high zone with moderate chargeability anomaly and overlapping magnetic low.
• Southside Zone: Moderate chargeability high with resistivity high contact, south side of the circular magnetic lobe.
• BullsEye: Magnetic high zone surrounded by magnetic low with moderate chargeability anomaly.

Figure 3: Fishpot exploration target areas

The maiden drill program is being designed to test multiple geological and geophysical targets across the property and provide the Company with its first systematic subsurface drilling dataset at Fishpot. Results from the drill program are expected to provide important information regarding geometry, continuity, geological controls and potential scale of mineralized systems identified through surface exploration and geophysical interpretation.

Millar Property

GoldInxs has decided to drop its interests in the Millar Property in order to focus resources on its core, road accessible and drill ready Fishpot Project given the near-term catalysts and discovery potential. The Company is actively pursuing other acquisitions of properties in North America.

Nick Michael, President and CEO of GoldInxs, commented:

“The Induced Polarization results represent one of the final pieces of information needed to further refine our drill targeting. The data has identified several compelling targets and strengthened our confidence in the areas we have prioritized for drilling. Most importantly, we are seeing strong convergence across multiple exploration datasets, allowing us to move from broad target generation to a focused maiden drill program designed to test some of the most compelling targets identified at Fishpot.The commencement of trading on the OTCQB is also an important corporate milestone for GoldInxs, supporting and improving the Company’s visibility and liquidity. It expands the Company’s accessibility to U.S. investors at an exciting stage in our exploration program, as we transition from systematic target generation toward the first drill testing at Fishpot.”

Qualified Person

The technical information contained in this news release has been reviewed and approved by Darcy Vis, P.Geo., the Qualified Person for GoldInxs Mining Corp., who is responsible for the technical information contained herein. The Company’s corporate presentation identifies Mr. Vis as the Qualified Person responsible for the technical information presented by GoldInxs.

Authorised for release by the Board of GoldInxs Mining Corp.

About GoldInxs

GoldInxs Mining Corp. (TSXV:INXS, OTCQB: INXGF) is a Canadian mineral exploration company focused on discovering and advancing a high-quality gold and copper project in Central British Columbia. The Company’s flagship asset is the Fishpot Property, a large epithermal gold system in central British Columbia with Blackwater-style exploration potential, and in the same region as Artemis Gold’s Blackwater Mine and Evolution Mining’s optioned Clisbako property. The Company is listed on the TSX Venture Exchange under the symbol INXS and on the OTCQB Venture Market under the symbol INXGF, and is led by an experienced management and technical team committed to disciplined exploration and value creation for shareholders.

Website: www.goldinxs.com      |     LinkedIn: LINK      |     Twitter/X: LINK

Further Information:

Barry Miller                        
Executive Chairman and Director
GoldInxs Mining Corp.
T: 778.232.1878
E: barry@goldinxs.com

Forward-Looking Statements

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively referred to herein as “forward-looking statements”) within the meaning of applicable securities legislation. Such forward-looking statements are based on a number of assumptions, which may prove to be incorrect. Assumptions have been made regarding, among other things: conditions in general economic and financial markets; accuracy of assay results; geological interpretations from exploration, survey, historic work, drilling results, timing and amount of capital expenditures; performance of available laboratory and other related services; future operating costs; and the historical basis for current estimates of potential quantities and grades of target zones. The actual results could differ materially from those anticipated in these forward-looking statements as a result of risk factors, including the timing and content of work programs; results of exploration activities and development of mineral properties; the interpretation and uncertainties of drilling results and other geological data; receipt, maintenance and security of permits and mineral property titles; environmental and other regulatory risks; project costs overruns or unanticipated costs and expenses; availability of funds; failure to delineate potential quantities and grades of the target zones based on historical data; and general market and industry conditions.

Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. Forward-looking statements in this news release include, but are not limited to, statements regarding the Company’s planned exploration activities at the Fishpot Property or any other Company properties, the timing, scope and objectives of the planned maiden drill program, the anticipated usefulness of geological, geochemical and geophysical data in refining exploration targets, potential exploration results, other prospective exploration projects, regional considerations, potential future financings of the Company and the potential benefits of the Company’s listing on the OTCQB Venture Market.

The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statements were made. The Company undertakes no obligation to update or revise any forward-looking statements included in this news release if these beliefs, estimates and opinions or other circumstances should change, except as otherwise required by applicable law.

Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/bfe5c0b8-9313-45b3-b711-262ed618d0b8

https://www.globenewswire.com/NewsRoom/AttachmentNg/2ed00ce5-97be-4d3b-9605-544a5458b544

https://www.globenewswire.com/NewsRoom/AttachmentNg/be70e054-86fd-4d61-991f-119a8edb9357 

NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received approval from the United States Food and Drug Administration (FDA) to implement a new potency assay, T-cell Proliferation Inhibition BioAssay (TIBA), for release and stability monitoring of all new commercial product lots of its FDA-approved mesenchymal stromal cell (MSC) product Ryoncil^® (remestemcel-L-rknd).

The TIBA assay will ensure sufficient sensitivity to detect any shifts in potency of the commercial product that could arise during changes in manufacturing processes or production in new facilities. This assay will be used as part of a matrix to release each commercial batch of RYONCIL in conjunction with the existing potency assays which determine IL-2Rα inhibition and CAP (Cell Adhesion and Proliferation), as per the product’s Biologics License. Together these assays ensure that the RYONCIL product is consistent, potent, and clinically effective.

RYONCIL is the first industrially-manufactured allogeneic MSC product approved by FDA for any indication, and the only MSC product to be approved for patients with steroid-refractory acute graft versus host disease (SR-aGvHD) aged 2 months or older.¹ Mesoblast and FDA have been working closely together since RYONCIL was approved for commercial use to ensure alignment on continued advancements to the product’s manufacturing processes and implementation of assays measuring the product’s ongoing quality control.

About Mesoblast
Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.

Mesoblast’s Ryoncil^® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at www.ryoncil.com.

Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Ryoncil^® is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China.

About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications provide commercial protection extending through to at least 2044 in all major markets.

About Mesoblast manufacturing: The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.

Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and X: @Mesoblast

Footnotes / References

1. Please see the full Prescribing Information at www.ryoncil.com

Forward-Looking Statements
This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast’s preclinical and clinical studies, and Mesoblast’s research and development programs; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast’s ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast’s RYONCIL for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast’s product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast’s ability to enter into and maintain established strategic collaborations; Mesoblast’s ability to establish and maintain intellectual property on its product candidates and Mesoblast’s ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast’s expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast’s financial performance; developments relating to Mesoblast’s competitors and industry; and the pricing and reimbursement of Mesoblast’s product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

Release authorized by the Chief Executive.

For more information, please contact:

Corporate Communications / Investors
Paul Hughes
T: +61 3 9639 6036
Media – Global	Media – Australia
Rubenstein	BlueDot Media
Caroline Nelson	Steve Dabkowski
T: +1 703 489 3037	T: +61 419 880 486
E: cnelson@rubenstein.com	E: steve@bluedot.net.au

To Nasdaq Copenhagen

FIXING OF COUPON RATES        24 September 2026

Fixing of coupon rates effective from 1 October 2026

Effective from 1 October 2026, the coupon rates of floating-rate bonds issued by Nykredit Realkredit A/S and Totalkredit A/S will be adjusted.

Bonds with quarterly interest rate fixing
The new coupon rates will apply from 1 October 2026 to 31 December 2026:

Uncapped bonds
DK0009518896, (32H), maturity in 2027, new rate as at 1 October 2026: 2.8422% pa
DK0009546087, (32H), maturity in 2027, new rate as at 1 October 2026: 2.7408% pa
DK0009546160, (32H), maturity in 2027, new rate as at 1 October 2026: 2.7307% pa
DK0009546244, (32H), maturity in 2027, new rate as at 1 October 2026: 2.7104% pa
DK0009546327, (32G), maturity in 2027, new rate as at 1 October 2026: 2.7713% pa
DK0009547721, (32H), maturity in 2027, new rate as at 1 October 2026: 2.8422% pa
DK0009548026, (32G), maturity in 2027, new rate as at 1 October 2026: 2.8524% pa
DK0009548109, (32H), maturity in 2028, new rate as at 1 October 2026: 2.8220% pa
DK0009548299, (32H), maturity in 2028, new rate as at 1 October 2026: 2.8118% pa
DK0009549859, (32H), maturity in 2029, new rate as at 1 October 2026: 2.8017% pa
DK0009549933, (32H), maturity in 2029, new rate as at 1 October 2026: 2.8118% pa
DK0009550006, (32G), maturity in 2028, new rate as at 1 October 2026: 2.8220% pa
DK0009551244, (32H), maturity in 2027, new rate as at 1 October 2026: 2.7915% pa
DK0009551400, (32H), maturity in 2028, new rate as at 1 October 2026: 2.6800% pa
DK0009551590, (32H), maturity in 2029, new rate as at 1 October 2026: 2.7408% pa
DK0009551673, (32H), maturity in 2029, new rate as at 1 October 2026: 2.6800% pa
DK0009551756, (32H), maturity in 2028, new rate as at 1 October 2026: 2.7104% pa
DK0009551913, (32H), maturity in 2030, new rate as at 1 October 2026: 3.1370% pa
DK0009552135, (32H), maturity in 2028, new rate as at 1 October 2026: 2.8017% pa
DK0009553885, (32H), maturity in 2029, new rate as at 1 October 2026: 2.6293% pa
DK0009553968, (32H), maturity in 2029, new rate as at 1 October 2026: 2.6293% pa
DK0009554180, (32H), maturity in 2029, new rate as at 1 October 2026: 2.6395% pa
DK0009554263, (32H), maturity in 2029, new rate as at 1 October 2026: 2.6395% pa
DK0009554503, (32H), maturity in 2030, new rate as at 1 October 2026: 3.0660% pa
DK0009554776, (32H), maturity in 2030, new rate as at 1 October 2026: 2.7408% pa
DK0009555740, (32H), maturity in 2028, new rate as at 1 October 2026: 2.6293% pa
DK0009766446, (49D), maturity in 2038, new rate as at 1 October 2026: 2.6395% pa
DK0009769622, (21E), maturity in 2041, new rate as at 1 October 2026: 2.6395% pa

Questions may be directed to Investor Relations at investor_relations@nykredit.dk or Press Officer Peter Klaaborg, tel +45 44 55 14 94.

Attachment

• Fixing of coupon rates – Nykredit Realkredit – 20260924

Descartes Datamyne™ AI Agent draws on data spanning 230 markets with more than 500 million shipment records annually to deliver traceable insights in seconds 

LONDON and ATLANTA, Sept. 24, 2026 (GLOBE NEWSWIRE) — Descartes Systems Group (Nasdaq:DSGX) (TSX:DSG), the global leader in uniting logistics-intensive businesses in commerce, announced the Descartes Datamyne™ AI Agent, a new conversational AI capability that helps sourcing, sales, supply chain and market intelligence teams reduce global trade data research and analysis time by up to 90%, depending on the user’s experience and query complexity. Embedded in the Descartes Datamyne global trade intelligence solution, the AI Agent allows users to ask questions in natural language and returns contextual answers in seconds, supported by dynamic visualizations and the underlying shipment records.

“Geopolitical disruption, tariff volatility and shifting sourcing patterns are making trade decisions more complex and time-sensitive,” said Brian Hodgson, General Manager, Trade Intelligence at Descartes. “By making trusted trade intelligence more accessible, the Descartes Datamyne AI Agent helps organizations understand where suppliers are gaining or losing activity, how product flows are changing, where market demand is emerging and how competitors are adapting. Users move quickly from a business question to validated insights on trends, risks and opportunities while retaining visibility into the records behind the analysis.”

Descartes Datamyne covers 230 markets with more than 500 million shipment records added annually. The AI Agent makes this extensive import and export data foundation easier to access, helping users identify suppliers, monitor competitors, evaluate trade risks, develop sales opportunities, and understand changing markets. In seconds, it responds to natural-language questions with relevant data, visualizations and contextual insights.

The Descartes Datamyne AI Agent helps users:

• Ask complex trade questions in natural language without building filters, using Boolean logic or mastering database query structures;
• Validate AI-generated findings through dynamically updated data views, visualizations and drill-down access to supporting shipment records;
• Explore insights within the same environment by refining questions and investigating related companies, commodities, shipments and trade relationships;
• Analyze actual trade behavior using observed shipment activity to understand changes in suppliers, buyers, product flows and market demand, rather than company descriptions, self-reported supplier profiles or general web content; and
• Improve supply chain planning with decision-ready summaries that highlight notable trends, anomalies, sourcing opportunities and other patterns across large volumes of trade records.

“AI is most useful when it combines trusted, domain-specific data with a clear connection to the decisions customers need to make,” said Ken Wood, EVP Product Management at Descartes. “The Agent analyzes shipment-level data and presents findings alongside the records and visual evidence supporting them, allowing users to verify conclusions, refine their questions and continue exploring without leaving the platform. Embedding the Agent directly into Descartes Datamyne gives customers a more transparent and intuitive way to accelerate decision-making and respond more effectively to changing global trade conditions.”

Learn more about the Descartes Datamyne AI Agent and Descartes’ Global Trade Intelligence solutions.

About Descartes

Descartes powers more responsive, efficient, secure and sustainable international and domestic supply chains by uniting logistics-intensive businesses on its Global Logistics Network (GLN). Shippers, carriers, and logistics service providers connect and collaborate on the GLN leveraging technology, data and AI to manage last mile deliveries, domestic and international shipments, transportation rating and payment, global trade research, customs compliance and a variety of regulatory processes. Learn more about Descartes at www.descartes.com and connect with us on LinkedIn and X.

Global Media Contact
Cara Strohack                                                                     
Tel: 226-750-8050                                 
cstrohack@descartes.com  

Cautionary Statement Regarding Forward-Looking Statements

This release contains forward-looking information within the meaning of applicable securities laws (“forward-looking statements”) that relate to Descartes’ global trade intelligence solution offerings and potential benefits derived therefrom, and other matters. Such forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements to differ materially from the anticipated results, performance or achievements or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the factors and assumptions discussed in the section entitled, “Certain Factors That May Affect Future Results” in documents filed with the Securities and Exchange Commission, the Ontario Securities Commission and other securities regulatory authorities across Canada including Descartes’ most recently filed annual and interim management’s discussion and analysis which are available under Descartes’ profile through the EDGAR website at http://www.sec.gov or through the SEDAR+ website at http://www.sedarplus.com/. If any such risks actually occur, they could, among other consequences, materially adversely affect our business, financial condition or results of operations. In that case, the trading price of our common shares could decline, perhaps materially. Readers are cautioned not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Forward-looking statements are provided for the purpose of providing information about management’s current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes. Except as required by applicable law, we do not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.